Latest Market Expectations News

The Savana US Small Caps Active ETF (ASX: SVNP) returned 2.21% in July 2026, beating the S&P SmallCap 600 benchmark by 5.44%, despite a sharp sell-off in semiconductor and AI infrastructure stocks. The fund’s disciplined, algorithm-driven approach helped navigate volatile market sentiment.

CSL Limited’s FY2026 results reveal modest revenue growth offset by a multibillion-dollar statutory loss driven by restructuring and impairments, alongside a maintained dividend and a strategic focus on sustainable growth.

L1 Group has partnered with Dr Andrew Lin to launch PXC Advisors, a global long short investment manager boasting a 51% annualised return since 2024. The strategy will open to external investors in September 2026 and take over management of the Platinum International Technology Fund.

Orora’s FY26 results reveal a $616.6 million statutory loss driven by a $742.8 million Glass impairment, offset by robust growth in its Cans business and disciplined capital management.

Corazon Mining (ASX:CZN) has kicked off a 2,000m reverse circulation drilling program at its Wembley gold prospect within the Feather Cap Project, aiming to test the continuity of historically high-grade, shallow gold mineralisation and explore a broader structural corridor in Western Australia’s Bryah-Padbury Basin.

Commonwealth Bank of Australia delivered a solid FY26 with 7% growth in net profit and a strong capital position, while continuing investments in AI and customer protection.

Wilson Asset Management's active portfolio surged 75.5% in FY2026, vastly outperforming benchmarks and underpinning a generous fully franked dividend. The fund's pivot to AI, critical minerals, and small resources sectors underpins a cautiously optimistic outlook amid market volatility.

Noxopharm reported significant progress in its Sofra technology, highlighting enhanced cancer drug potential and preparations for a US FDA clinical trial, while managing tight cash reserves.

Ovanti appoints two early Afterpay executives to its Advisory Board as it prepares to relaunch its BNPL platforms IOUPAY and myIOU, targeting rapid growth in Southeast Asia and beyond.

Noxopharm has taken a key regulatory step by requesting a pre-IND meeting with the US FDA for its autoimmune drug candidate SOF-SKN, aiming to smooth the path for clinical development and boost its commercial appeal.

WhiteHawk Limited has appointed Adrian Vallino as Group CEO to spearhead its global expansion and commercialisation of the Quixxi Clarity AI platform, aiming to grow recurring revenue and diversify its distribution channels.

Nimy Resources (ASX: NIM) responds to ASX query following a sharp share price fall, confirming pending assay results from recent sampling but no undisclosed information explaining the trading.